Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer [scATAC-seq]

ABSTRACT: Cancer cells often adapt a stem-like state resulting in lineage plasticity and phenotypic heterogeneity. We assessed the dynamics of lineage determination and cellular subpopulation expansion in treatment-resistant adenocarcinoma, amphicrine, and small cell neuroendocrine castrate resistant prostate cancers.

ORGANISM(S): Homo sapiens

PROVIDER: GSE237601 | GEO | 2023/07/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer [scRNA-seq]

Project description:Cancer cells often adapt a stem-like state resulting in lineage plasticity and phenotypic heterogeneity. We assessed the dynamics of lineage determination and cellular subpopulation expansion in treatment-resistant adenocarcinoma, amphicrine, and small cell neuroendocrine castrate resistant prostate cancers.

2023-07-24 | GSE237602 | GEO

The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer [scATAC-seq]

Project description:The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer [scATAC-seq]

| PRJNA995801 | ENA

The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer.

Project description:The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer.

| PRJNA995798 | ENA

The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer [scRNA-seq]

Project description:The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer [scRNA-seq]

| PRJNA995802 | ENA

Gene expression signature of castrate resistant prostate cancer

Project description:Prostate gland is a highly androgen dependent gland. The first line of treatment for metastatic prostate cancer therefore, is androgen ablation. This can be achieved by multiple non-surgical methods. However, most of these cancers although respond well initially, become resistant to androgen ablation sooner or later. These cancers then become extremely aggressive and difficult to treat, thereby drastically affect the patient prognosis. A gene expression signature for castrate resistant prostate cancer would be useful in identification of mechanisms responsible for castrate resistance, as well as to predict the progression of the cancer into castrate resistance. For this, our group has done a RNA-seq analysis of a. Control group (C); b. Castrate Sensitive group (B) and c. Castrate Resistant group (A). Gene expression profiling was performed on these samples using RNA-seq. Differentially expressed genes between control and castrate sensitive as well as control and castrate resistant groups were identified.

2024-09-11 | GSE262940 | GEO

The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer.

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-07-24 | GSE237603 | GEO

Hes6 drives a network with therapeutic potential in castrate-resistant prostate cancer

Project description:Castrate-resistant prostate cancer (CRPC) is poorly characterized and heterogeneous and while the androgen receptor (AR) is of singular importance in early prostate cancer, other factors such as c-Myc and the E2F family also play a role in later stage disease. Hes6 is a transcription co-factor that has been associated with neurogenesis during gastrulation, a neuroendocrine phenotype in the prostate and metastasis in breast cancer but its role in prostate cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and AR and drives castration resistance in prostate cancer. Hes6 activates a cell-cycle enhancing transcriptional network that maintains tumour growth and nuclear AR localization in castrate conditions. We show aphysical interaction between E2F1 and both Hes6 and AR, and suggest a co-dependency of these transcription factors in castration-resistance. In the clinical setting, we have uncovered a Hes6-associated signature that predicts poor outcome in prostate cancer, which can be pharmacologically targeted. We have therefore shown for the first time the critical role of Hes6 in the development of CRPC and identified its potential in patient specific therapeutic strategies. This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-04-17 | E-GEOD-36526 | biostudies-arrayexpress

Proteomic analysis of castrate resistant prostate cancer cell lines

Project description:In this study the development of androgen independence in a cell model of disease was selected as a mirror of to the events at play in the development of Castrate Resistant Prostate Cancer in-vivo. LNCaP cells which are androgen dependent and androgen independent sublines; LNCaP-Abl and LNCaP-Abl-Hof were subject to extensive fractionation by 1-D SDS PAGE and accurate mass-high resolution mass spectrometry (Q Exactive) to identify proteins whose expression was changes significantly in response to androgen independent growth.

2022-02-28 | PXD000751 | Pride

Hes6 drives a network with therapeutic potential in castrate-resistant prostate cancer

2014-04-17 | GSE36526 | GEO

The METTL3 RNA methyltransferase regulates androgen signalling in castrate resistant prostate cancer cells

Project description:iRNAs targeting METTL3 used to deplete METTL3 in castrate resistant LNCaP:C42 and 22Rv1 prosate cancer cells and the effect on basal and androgen regulated gene expression and splicing determined.

2022-11-02 | GSE194420 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data